Strong Cresemba® (isavuconazole) sales in Europe trigger USD 37.5 million milestone payment to Basilea

What happened

Basilea Pharmaceutica said strong European sales of its antifungal Cresemba by license partner Pfizer triggered a USD 37.5 million milestone payment to Basilea. Global in-market Cresemba sales reached USD 817 million in the twelve months from July 2025 to June 2026, up 25 percent year-on-year.

Confirmed

Global impact / market context

A milestone payment is cash Basilea receives without selling new shares or borrowing, so it directly boosts the cash available to fund research and development. Because the payment was triggered by Pfizer's European sales, Basilea's revenue can rise even without its own selling effort, improving profit per sale.

Analyst inference

Cresemba is described as the largest branded antifungal for invasive fungal infections worldwide, with sales spread across more than 70 countries. That scale matters because a drug still growing 25 percent a year can keep generating milestone payments and royalties for Basilea, which depends on partners such as Pfizer to sell it in major markets.

Analyst inference

What to watch

1. Basilea disclosed the USD 37.5 million milestone and reported global Cresemba in-market sales of USD 817 million for the twelve months from July 2025 to June 2026, a 25 percent increase year-on-year. Confirmed
2. Watch whether Basilea states how it will use the USD 37.5 million, such as funding its research and development portfolio, which means the pipeline of experimental therapies the company is developing. Proposed
3. Track future European Cresemba sales reported by Pfizer, because sustained growth could trigger further milestone payments and royalties, lifting Basilea's revenue and the cash available to reinvest in new treatments. Analyst inference

Evidence

• globenewswire.com